Review of Current Treatments for Parkinson's Disease
DOI:
https://doi.org/10.58445/rars.405Keywords:
Parkinson's Disease, dopamine, deep brain stimulation, blood-brain barrier, neurotransmitter, tremors, on-off cycles, rehabilitation, anticholinergics, somatic stem cellsAbstract
This review paper comprehensively examines the current landscape of treatment strategies for Parkinson's Disease (PD). Parkinson's Disease is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremors, and rigidity, along with non-motor symptoms including cognitive impairments and psychiatric disturbances. In this
review, we cover several treatments that were reported in the literature, their efficacy, as well as how these treatments could be improved. The management of PD has evolved significantly over the years, driven by advancements in both pharmacological and non-pharmacological interventions. This paper provides an up-to-date overview of the various treatments available, ranging from levodopa therapy to dopamine agonists, monoamine oxidase-B inhibitors, and anticholinergics. Non-pharmacological interventions, including deep brain stimulation, physical therapy, and cognitive rehabilitation, are also discussed for their crucial roles in augmenting symptom management and improving quality of life.
References
References
Poustinchi M, Musallam S. Towards an implantable intelligent CMOS neurotrophic factor
delivery micro neural prosthetic for Parkinson’s disease. In: 2013 6th International IEEE/EMBS
Conference on Neural Engineering (NER) [Internet]. San Diego, CA, USA: IEEE; 2013 [cited
Jun 29]. p. 863–7.
Xu J, Gong DD, Man CF, Fan Y. Parkinson’s disease and risk of mortality: meta-analysis and
systematic review. Acta Neurol Scand. 2014 Feb;129(2):71–9.
Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, et al. Adaptive deep brain stimulation
in advanced Parkinson's disease. Ann Neurol. 2013 Sep;74(3):449–57.
Okun MS. Deep-Brain Stimulation for Parkinson’s Disease. N Engl J Med. 2012 Oct
;367(16):1529–38.
Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of
Parkinson’s disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121–34.
Hussein A, Guevara CA, Del Valle P, Gupta S, Benson DL, Huntley GW. Non-Motor Symptoms
of Parkinson’s Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction.
Neuroscientist. 2023 Feb;29(1):97–116.
Pinjala P, Tryphena KP, Prasad R, Khatri DK, Sun W, Singh SB, et al. CRISPR/Cas9 assisted
stem cell therapy in Parkinson’s disease. Biomater Res. 2023 May 16;27(1):46.
Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA.
;323(6):548–560. doi:10.1001/jama.2019.22360
CTG Labs - NCBI
clinicaltrials.gov/study/NCT03103919?cond=Parkinson+Disease&aggFilters=results%3Awit
h%2Cstatus%3Acom&rank=1. Accessed 31 Aug. 2023.
CTG Labs - NCBI,
clinicaltrials.gov/study/NCT03841604?cond=Parkinson+Disease&aggFilters=results%3Awit
h%2Cstatus%3Acom&rank=2. Accessed 31 Aug. 2023.
CTG Labs - NCBI,
clinicaltrials.gov/study/NCT03700684?cond=Parkinson+Disease&aggFilters=results%3Awit
h%2Cstatus%3Acom&rank=4. Accessed 31 Aug. 2023.
CTG Labs - NCBI,
clinicaltrials.gov/study/NCT03204526?cond=Parkinson+Disease&aggFilters=results%3Awit
h%2Cstatus%3Acom&intr=Deep+brain+stimulation&rank=3. Accessed 31 Aug. 2023.
CTG Labs - NCBI,
clinicaltrials.gov/study/NCT00391898?cond=Parkinson+Disease&aggFilters=results%3Awit
h%2Cstatus%3Acom&intr=Carbidopa%2Flevodopa&rank=1. Accessed 31 Aug. 2023.
Additional Files
Posted
Categories
License
Copyright (c) 2023 Lithesh Gorijala, Omar Tawakol
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.